About Prestwick Pharmaceuticals
Prestwick Pharmaceuticals is a Healthcare company based in Washington (United States) founded in 2002, and was acquired by Biovail in September 2008. Small molecule drugs for chronic CNS diseases are developed. Prestwick Pharmaceuticals has raised $103.79 million across 6 funding rounds from investors including Warburg Pincus, FirstMark and Atlas Venture. Prestwick Pharmaceuticals offers products and services including Antibodies, Assay Kits, ELISA Kits, and PCR Kits. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative.
Company details
Prestwick Pharmaceuticals was founded in 2002 as a specialty pharmaceutical company focused on the development and commercialization of small molecule drugs targeting chronic central nervous system diseases. Operations included early-stage products such as Lisuride for Parkinsons disease and D-Serine for schizophrenia. An exclusive U.S. commercialization agreement for Xenazine in Huntingtons disease was established with Ovation Pharmaceuticals. The company was acquired by Biovail Corp. in September 2008.
- Headquarters Washington, United States
- Stage Acquired
- SectorsHealthcare
- Website prestwickpharma.com
- Acquired by Biovail (Sep 2008)
- Total Equity Funding$103.79M (USD)
in 6 rounds
- Latest Funding Round$20M (USD), Series C
Aug 2007
- InvestorsWarburg Pincus
& 7 more
- Acquired byBiovail
(Sep 2008)
Products & Services of Prestwick Pharmaceuticals
Prestwick Pharmaceuticals offers a comprehensive portfolio of products and services, including Antibodies, Assay Kits, ELISA Kits, and PCR Kits.
Used for detecting specific proteins in research and diagnostics.
Kits for testing biological samples in various assays.
Tools for enzyme-linked immunosorbent assays in disease detection.
Kits for polymerase chain reaction in DNA amplification.
Funding Insights of Prestwick Pharmaceuticals
Prestwick Pharmaceuticals has successfully raised a total of $103.79M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in August 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $103.79M
- Total Rounds 6
- Last Round Series C — $20M
- First Round $15M
(Jun 2003)
- Investors Count 7
All 6 funding rounds of Prestwick Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2007 | $20M | Series C | – | – | |
| Aug 2007 | $59,422 | Debt – Convertible | – | – | – |
| Aug 2006 | $31.79M | Series C | – | – | |
| Dec 2004 | $37M | Series B | – | – | |
| Nov 2004 | $8.14M | Debt – Convertible | – | – | – |
| Jun 2003 | $15M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Prestwick Pharmaceuticals
Prestwick Pharmaceuticals has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Warburg Pincus, FirstMark and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Early-stage venture capital is invested in tech startups across sectors. | 1987 | firstmark.com | New York, United States | |
Early-stage venture capital investments are focused on US companies. | scalevp.com | Foster City, United States | ||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Multi-stage private equity investments are pursued across diverse sectors. | 1966 | warburgpincus.com | New York, United States | |
Wealth is managed for the Clark family by Clark Enterprises. | clarkenterprises.com | Bethesda, United States | ||
R&D company focused on manufacturing of drugs for multiple therapeutic areas | 1983 | biovail.com | Mississauga, Canada |
Investor details for Prestwick Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Prestwick Pharmaceuticals
4 dated milestones of Prestwick Pharmaceuticals across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Prestwick Pharmaceuticals is founded.
- Funding First funding round of $15.0M.
- Funding Latest funding round, Series C, of $20.0M.
- Exit Acquired by Biovail.
Top companies in Neurology
3 companies that operate in the same segment as Prestwick Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prestwick Pharmaceuticals
Complete news archive for Prestwick Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prestwick Pharmaceuticals
Prestwick Pharmaceuticals was founded in 2002 and raised its 1st funding round 1 year after it was founded.
Prestwick Pharmaceuticals is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.
Prestwick Pharmaceuticals is a funded company, having raised a total of $103.79M across 6 funding rounds to date. The company's 1st funding round was a Series A of $15M, raised on Jun 2003.
Prestwick Pharmaceuticals was founded in 2002 as a specialty pharmaceutical company focused on the development and commercialization of small molecule drugs targeting chronic central nervous system diseases. Operations included early-stage products such as Lisuride for Parkinsons disease and D-Serine for schizophrenia. An exclusive U.S. commercialization agreement for Xenazine in Huntingtons disease was established with Ovation Pharmaceuticals. The company was acquired by Biovail Corp. in September 2008.
Prestwick Pharmaceuticals offers Antibodies, Assay Kits, ELISA Kits, and PCR Kits.
Prestwick Pharmaceuticals has 8 investors. Key investors include Warburg Pincus, FirstMark, Atlas Venture, Biovail, and Scale Venture Partners.
Yes. Prestwick Pharmaceuticals was acquired by Biovail in September 2008.